Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 270

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 270
---
 Recommendation of the Iris Board
<div align='center'>THE IRIS BOARD UNANIMOUSLY RECOMMENDS THAT IRIS STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE INCENTIVE PLAN PROPOSAL.

130</div>

TABLE OF CONTENTS

#### PROPOSAL NO. 4 — THE PARENTCO CHARTER PROPOSAL

### Overview
In connection with the Business Combination, Iris is asking its stockholders to approve the adoption of the ParentCo Certificate of Incorporation in the form attached to this proxy statement/prospectus as Annex C , which, in the judgment of the Iris Board, is necessary to adequately address the needs of Liminatus following the consummation of the Business Combination.

The following is a summary of the key changes between the Iris Certificate of Incorporation and the ParentCo Certificate of Incorporation. This summary is qualified by reference to the complete text of the ParentCo Certificate of Incorporation. All stockholders are encouraged to read the ParentCo Certificate of Incorporation in its entirety for a more complete description of its terms.

• Name Change . Change the corporate name from “Iris Acquisition Corp” to “Iris Parent Holding Corp.” as of the closing;

• Authorized Share Capital . Change the total number of shares of all classes of authorized capital stock from 300,000,000 shares of common stock, including 280,000,000 shares of Iris Class A Common Stock and 20,000,000 shares of Class B Common Stock, and 1,000,000 shares of preferred stock, to 501,000,000 shares of common stock, consisting of 500,000,000 shares of common stock and 1,000,000 shares of preferred stock;

• Dual-Class Capital Structure . Eliminate Class B Common Stock and any rights of holders thereof;

• Amendment . Provide that the affirmative vote of two-thirds of the total voting power of all the then outstanding shares of stock, shall be required to amend or repeal part (b) of Article IV, Article V, Article VI, Article VII, Article VIII, Article IX and Article X;

• Blank Check Company . Remove the provisions under Article IX (Business Combination Requirements; Existence) relating to Iris’s status as a blank check company; and

• Corporate Opportunity . Remove the provisions under Article X (Corporate Opportunity) relating to the application of the doctrine of corporate opportunity. Although Iris had previously waived the corporate opportunities doctrine, this did not impact Iris’s search for